[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"medication-overuse-headache\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:medication-overuse-headache":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,79,104,128,156],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100600915","i-need-new-migraine-drugs-database-100600915",false,"NCT07103694","i-NEED: NEw migrainE Drugs Database","Italian Real-life Multicenter Observational Study on Efficacy, Tolerability, and Safety of Innovative Drugs (Monoclonal Antibodies, Gepants, Ditans, Sumatriptan-naproxen) for Preventive or Acute Migraine Treatment.","i-NEED","Inclusion Criteria:\n\n* Age more or equal 18 years;\n* Males and females;\n* Willingness to sign the informed consent;\n* Episodic migraine for the use of drug indicated for migraine attack\n* High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months;\n* Chronic migraine, according to the ICHD-III criteria;\n\nExclusion Criteria:\n\n* Other headaches different than migraine;\n* Known intolerance to the eccipients;\n* Vascular disease or Raynaud.","ALL","18 Years",{"count":20,"type":21},2641,"ESTIMATED","3 Years","OBSERVATIONAL","Approved by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) starting in 2018, anti-CGRP monoclonal antibodies (anti-CGRP mAbs) represent the first true revolution in the preventive treatment of migraine due to their selectivity and specificity. To date, four anti-CGRP mAbs have been developed for the preventive treatment of migraine: eptinezumab, erenumab, fremanezumab, and galcanezumab.Anti-CGRP mAbs constitute not only the first specific and selective treatment for the prevention of migraine but also the most extensively studied pharmacological category in this field, considering the vast and complex populations examined. The clinical effects of the various mAbs are substantially comparable and are characterized by several fundamental aspects:\n\n* High efficacy in both episodic and chronic migraine, with the presence of super-responders who experience a reduction in the average monthly number of migraine days of \\>75% (or even 100%) compared to before treatment.\n* Efficacy that is independent of the clinical form of migraine - with or without aura - and regardless of whether there is analgesic overuse.\n* Efficacy maintained even in the presence of depressive or anxious comorbidities.\n* Rapid onset of action (even more pronounced with eptinezumab), with the therapeutic effect appearing within the first week in most cases.\n* Excellent tolerability with an absence of class-specific adverse events.\n* Outstanding treatment adherence and a very low rate of treatment discontinuation in the long term. It should also be noted that the development of anti-drug antibodies or neutralizing antibodies to anti-CGRP mAbs is rare and does not significantly impact the efficacy or tolerability of treatment. Future clinical practice will need to clarify several additional aspects, such as: 1) whether treatment with anti-CGRP mAbs can modify the course of migraine; 2) the appropriate approach regarding any traditional preventive treatment (whether to continue or discontinue it); 3) the definition of the characteristics of non-responders; 4) the definition of patients with a delayed response to treatment.\n\nGepants are oral antagonists of the CGRP receptor. Among the four gepants synthesized so far (atogepant, rimegepant, ubrogepant, zavegepant), atogepant and rimegepant are currently available in Italy. Atogepant has proven to be an effective and well-tolerated option for the prevention of episodic and chronic migraines. Rimegepant is effective for both acute treatment and prevention of migraines, with a favorable safety profile and flexible oral administration. Lasmiditan is the first ditan effective for migraine attack and it represents a new therapeutic option for patients with contraindications to triptans, due to the presence of vascular risk factors, or for patients who experience undesirable side effects with these, thus increasing the therapeutic possibilities for the symptomatic treatment of migraine. The combination of sumatriptan 85 mg and naproxen sodium 500 mg is indicated for the acute treatment of migraine attacks in adult patients for whom sumatriptan monotherapy is insufficient.",[26,27,28],"Episodic Migraine","Chronic Migraine","Medication Overuse Headache",[30],"migraine, anti-CGRP monoclonal antobodies, gepants, ditans, sumatriptan and naproxen combination","RECRUITING","2026-06-09",{"date":34,"type":35},"2026-06-11","ACTUAL",{"date":37,"type":35},"2022-03-24",{"date":39,"type":21},"2026-12-31",{"name":41,"class":42},"IRCCS San Raffaele Roma","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100636654","greater-occipital-nerve-block-for-migraine-with-medication-overuse-headache-100636654","NCT07568496","Greater Occipital Nerve Block for Migraine With Medication Overuse Headache","GONB_MOH","Inclusion Criteria:\n\n* Patients who have a diagnosis of migraine with medication overuse headache according to ICHD-3 criteria confirmed by a neurologist\n* Female patients will be screened for pregnancy planning and married female patients must undergo a urine pregnancy test\n\nExclusion Criteria:\n\n* Patients who have other types of headache disorders other than migraine\n* Patients who have a previous history of allergy to corticosteroid or lidocaine\n* Patients who had previous skull surgery\n* Pregnant women\n* Patients with a history of uncontrolled depression, or psychosis\n* Patients who get or plan to get CGRP-targeted therapies or botulinum toxin injection\n* Patients with an increased risk of bleeding or underlying bleeding disorders","80 Years",{"count":53,"type":21},130,"INTERVENTIONAL",[56],"NA","Migraine is among the leading causes of disability worldwide. Inappropriate use of acute medications in the setting of primary headache, particularly migraine can result in a debilitating condition known as medication overuse headache (MOH). Treatment of MOH is challenging and the primary therapeutic approach is reducing painkillers which helps decrease the number of headache days. As a part of the detoxification process to discontinue acute medications, bridging therapy is often needed to reduce withdrawal headache. Currently, there are data supporting the use of greater occipital nerve block as a preventive treatment in chronic migraine, but no placebo-controlled trial has evaluated the efficacy of greater occipital nerve block in MOH. Therefore, this research aims to demonstrate the efficacy of greater occipital nerve block in detoxification of migraine patients with MOH. Patients will be recruited from Headache Clinic at 3 centers in Thailand from February 2026 to January 2028. After recruitment, patients will be randomized into 2 groups at a 1:1 ratio using a block of four, namely group A and B. A 5-mL syringe of 2 mL of lidocaine 2% and 2 mL of methylprednisolone 40 mg\u002FmL (80 mg) will be prepared for each patient in group while a 5-mL syringe of 4 mL normal saline will be prepared for each patient in group B. Monthly headache days, duration, severity, acute medication type and number of usage days and relative headache status according to a 5-point Likert scale will be investigated at the 2 weeks, 1st, 2nd and 3rd month, MIDAS at the end of 3rd month.",[59,28,60],"Migraine Disorders","Greater Occipital Nerve Block",[62,63,64,65,66,67],"GONB","Nerve Block","Detoxification","MOH","Methylprednisolone","Lidocaine","NOT_YET_RECRUITING","2026-05-11",{"date":71,"type":35},"2026-05-13",{"date":73,"type":21},"2026-05-01",{"date":75,"type":21},"2028-11-01",{"name":77,"class":42},"Mahidol University",3,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100630436","treatment-response-in-patients-with-medication-overuse-headache-100630436","NCT07487649","Treatment Response in Patients With Medication-Overuse Headache","Factors Affecting Treatment Response in Patients With Medication-Overuse Headache Undergoing Greater Occipital Nerve Blockade","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Diagnosis of medication-overuse headache according to the International Classification of Headache Disorders, 3rd edition (ICHD-3)\n* Diagnosis of medication-overuse headache associated with the use of triptans or nonsteroidal anti-inflammatory drugs\n* Previous diagnosis of chronic migraine or chronic tension-type headache according to the ICHD-3 criteria\n\nExclusion Criteria:\n\n* History of severe head or neck trauma or previous neurosurgical intervention\n* Presence of a severe psychiatric disorder (e.g., severe depression, schizophrenia)\n* History of infectious disease, chronic inflammatory disease, or malignancy\n* Previous diagnosis of secondary headache\n* History of substance abuse\n* Pregnancy or breastfeeding\n* History of an additional neurological disorder (e.g., cerebrovascular disease, multiple sclerosis)\n* Difficulty with cooperation\n* Presence of a concomitant systemic disease that may affect quality of life (e.g., congestive heart failure, chronic kidney disease, chronic liver disease, pulmonary disease, uncontrolled diabetes, or peripheral vascular disease)","65 Years",{"count":88,"type":21},70,"The aim of this study to evaluate pre-injection patient-related factors that may influence treatment response in patients with medication-overuse headache who underwent ultrasound-guided greater occipital nerve block.",[91,92,93,60],"Medication-overuse Headache","Treatment","Headache","2026-03-17",{"date":96,"type":35},"2026-03-23",{"date":94,"type":35},{"date":99,"type":21},"2026-05-30",{"name":101,"class":102},"Sultan 1. Murat State Hospital","OTHER_GOV",1,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":112,"targetDuration":4,"studyType":54,"phases":114,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":124,"leadSponsor":126,"locationsCount":103},"100620681","personalized-pulsed-radiofrequency-of-the-greater-occipital-nerve-for-medication-overuse-headache-100620681","NCT07360782","Personalized Pulsed Radiofrequency of the Greater Occipital Nerve for Medication Overuse Headache","Individualized Application of Occipital Nerve Pulsed Radiofrequency in Medication Overuse Headache: A Randomized Controlled Evaluation","PRIMOGON","Inclusion Criteria\n\n* Age 18-65 years\n* Diagnosed with Medication Overuse Headache (MOH) according to ICHD-3 criteria\n* No laboratory evidence of bleeding or clotting disorders\n* No active infection\n* Not pregnant and no suspicion of pregnancy\n* No history of craniocervical surgery that may alter anatomical structures at the intervention site\n* Able to understand the study procedures, provide written informed consent, and comply with treatment\n\nExclusion Criteria\n\n* Changes in preventive treatment for migraine and\u002For tension-type headache within the last 3 months\n* Severe systemic disease (e.g., uncontrolled diabetes, serious cardiovascular disease, malignancy)\n* Psychiatric disorders (including current antidepressant use or psychiatric follow-up)\n* History of alcohol or substance abuse\n* Pregnancy, breastfeeding, or plans for pregnancy in the next 12 months\n* Concurrent use of other prophylactic headache treatments",{"count":113,"type":21},90,[56],"This study evaluates a novel treatment approach for medication overuse headache (MOH) using greater occipital nerve pulsed radiofrequency (GONPRF).\n\nThree treatment strategies are compared:\n\nStandard Treatment: Limitation of overused acute headache medications, lifestyle counseling, and continuation of existing preventive medications.\n\nPrimary GONPRF: GONPRF administered in addition to standard treatment.\n\nModified GONPRF: GONPRF administered as a second-line intervention in individuals who do not respond adequately to standard treatment alone.\n\nThe study assesses whether GONPRF, when applied early or after an initial period of standard care, reduces monthly headache days more rapidly and effectively than standard treatment alone. Outcomes are evaluated over a 6-month follow-up period using headache diaries and scheduled clinical assessments.\n\nThis is a randomized controlled trial designed to systematically evaluate the clinical benefit of GONPRF in patients with medication overuse headache.",[28],[28,118,119],"Occipital Nerve Pulsed Radiofrequency","Headache Treatment","2026-01-26",{"date":122,"type":35},"2026-01-27",{"date":120,"type":35},{"date":125,"type":21},"2027-08",{"name":127,"class":42},"Ankara City Hospital Bilkent",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":135,"maxAge":4,"enrollmentInfo":136,"targetDuration":138,"studyType":23,"phases":4,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100464994","china-headache-disorders-registry-100464994","NCT05334927","China HeadAche DIsorders RegiStry","CHAIRS","Inclusion Criteria:\n\n1. Age ≥ 12 years old,Any gender;\n2. The first onset age of primary headache was less than 50 years old(Age \\\u003C65 years at first diagnosis of chronic migraine);\n3. patients with primary headache (migraine, tension headache and other types of primary headache) or primary headache complicated with MOH according to ICHD-3;\n4. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. According to the ICHD-3 diagnostic criteria, there are still headaches directly related to secondary factors (except drug overuse) at the time of enrollment;\n2. Those who cannot be diagnosed as primary headache or primary headache combined with medication overuse headache according to ICHD-3;\n3. According to DSM-V diagnostic criteria, patients with severe mental diseases (such as schizophrenia, mental disorders associated with mental retardation, etc.);\n4. Patients with severe organic diseases, such as malignant tumors, and the expected survival time is less than 1 year;\n5. Pregnant,planning pregnancy or Lactating women;\n6. Subjects participating in other clinical trials;\n7. Unable to cooperate to complete the follow-up due to geographical or other reasons","12 Years",{"count":137,"type":21},10000,"1 Month","It is planned to include 10000 patients. In the China HeadAche DIsorders RegiStry CHAIRS）, patients aged over 12 years with primary headache and medication-overuse headache(MOH) were collected. The biomarkers, imaging features, cognition, genetic characteristics, ocial and demographic data, medical data, therapeutics used, and outcome of headache-related diseases were studied, and long-term follow-up was planned.",[141,142,143,28,144,145],"Headache Disorders, Primary","Migraine","New Daily Persistent Headache","Tension-Type Headache","Trigeminal Autonomic Cephalalgia","2026-01-12",{"date":148,"type":35},"2026-01-15",{"date":150,"type":35},"2022-08-29",{"date":152,"type":21},"2032-12-31",{"name":154,"class":42},"Beijing Tiantan Hospital",20,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":163,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":164,"targetDuration":4,"studyType":54,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":103},"100577759","efficacy-and-central-mechanisms-of-electroacupuncture-for-medication-overuse-headache-100577759","NCT06802471","Efficacy and Central Mechanisms of Electroacupuncture for Medication Overuse Headache","Efficacy and Central Mechanism of Electroacupuncture for Medication Overuse Headache: a Multicenter Randomized Controlled Trial","Inclusion Criteria for Patients with MOH:\n\n* Meet the diagnostic criteria of MOH in ICHD-3;\n* A history of migraine (according to ICHD-3 criteria)\u002Ftension headache (TTH) (according to ICHD-3 criteria) for ≥12 months before screening;\n* Patients entered data from the electronic headache diary for at least 24 of the 28 days of the screening period (evidence of good adherence to the electronic headache diary);\n* Prospectively collected data from the electronic headache diary during the screening period met the following criteria: 15 or more headache days per month; Regular overdose of acute or symptomatic headache medications meets the diagnostic criteria for MOH；\n* Headache diagnosed before the age of 50 years;\n* Patients had failed MOH withdrawal treatment (with medical documentation or specific physician confirmation of each treatment) on ≥1 occasions in the previous 3 years; Withdrawal treatment failure is defined as no significant reduction in headache frequency, duration and\u002For severity after withdrawal treatment; Or intolerable withdrawal reactions during withdrawal treatment; Or unable to quit treatment due to safety issues;\n* Aged between 18 and 80 years old;\n* Signed the informed consent and volunteered to participate in the study.\n* Patients who met the above 8 criteria were included in this study.\n\nExclusion Criteria for Patients with MOH:\n\n* Patients had a history or diagnosis of hypotensive headache, continuous hemiplegia, new daily persistent headache, or unusual migraine subtypes, such as hemiplegic migraine (sporadic and familial), ocular tension migraine, migraine with neurologic symptoms that were atypical of migraine aura (diplopia, altered consciousness, or prolonged duration). Other types of primary or secondary headache;\n* The presence of clinically significant pain syndromes that may be confusing (e.g., fibromyalgia, chronic low back pain, complex regional pain syndrome); Acute or active temporomandibular joint disorders;\n* The patient had an uncontrolled and\u002For untreated mental illness (e.g., severe depression and schizophrenia) for at least 6 months prior to the screening visit; Patients with a history of psychosis and\u002For mania within 5 years before screening were excluded;\n* The patient has any other medical condition whose treatment takes precedence over MOH treatment or may interfere with the study treatment or impair compliance with treatment;\n* Taking\u002Fusing medications\u002Fstimulation devices that may affect headache (e.g., beta-blockers (atenolol, propranolol, metoprolol, etc.) due to headache or other reasons within 3 months before or during the screening period; Calcium channel blockers (flunarizine, benzothiazide, etc.); Antidepressants (amitriptyline, venlafaxine, duloxetine, etc.); Antiepileptic drugs (topiramate, sodium valproate, carbamazepine, etc); Angiotensin-receptor blockers (candesartan and lisinopril); Botulinum toxin; Gabapentin; Noninvasive vagus nerve stimulation, transcranial magnetic stimulation, peripheral trigeminal nerve stimulation; Biofeedback, health products; Occipital nerve block, other nerve block; Continuous infusion therapy, steroid reduction; Chiropractic therapy, physical therapy); Or treatment with injections (trigger point injections, extracranial nerve blocks or facet joint injections) on the head, face or neck;\n* The patient has a history of moderate or severe head or neck trauma, or other neurological or systemic diseases (such as epilepsy and dementia) that the researcher believes may affect the central nervous system function;\n* Patients have or have had one or more of the following conditions that were considered in the study to be associated with clinical symptoms: other neurological, pulmonary, hepatic, endocrine, gastrointestinal, hematologic, infectious, immunologic, or ocular conditions;\n* A history of substance or alcohol abuse (according to DSM-5® criteria) within 24 months prior to the screening visit;\n* During the screening or baseline visit, the patient has significant suicide risk (answers \"Yes\" to question 4 or 5 on the C-SSRS suicide ideation section, or answers \"Yes\" to any question regarding suicidal behavior at any time during the study on the C-SSRS);\n* Prophylactic treatment for headache was received 1 month before the screening visit;\n* One month before the screening visit, the patient had participated in a clinical study; Or had taken any medication for headache within the 5 plasma half-lives, whichever was longer, before the screening visit;\n* Severe uncontrolled disease such as cancer, uncontrolled cardiovascular disease, severe hepatic and renal insufficiency, or coagulopathy; Women who are pregnant or preparing to become pregnant;\n* Having known fear of acupuncture or having received acupuncture treatment within 8 weeks before enrollment;\n* In the judgment of the investigators, the patients have diseases or take drugs that may affect the assessment of the safety, tolerability, or efficacy of the trial, or affect the conduct or interpretation of the study.\n* Any one of the above items is excluded.\n\nInclusion Criteria for Patients with episodic migraine(Control group 1):\n\n* According to the ICHD-3 criteria, it met the diagnostic criteria of episodic migraine; With\u002Fwithout tension-type headache;\n* Headache days\u002Fmonth ≤6 days at enrollment;\n* The number of days\u002Fmonth of using analgesics at enrollment was ≤6 days;\n* Age between 18 and 80 years;\n* Be able to fill out a headache diary;\n* No previous history of drug abuse;\n* No obvious comorbidities pain, physical or mental disorders;\n* No alcohol or drug addiction;\n* No pregnancy, breastfeeding, or plans for pregnancy in the next 12 months;\n\nInclusion Criteria for Healthy Participants(Control group 2):\n\n* No headache or headache ≤2 days in the past 12 months at enrollment;\n* No more than 6 days\u002Fmonth of use of analgesics at enrollment;\n* Age between 18 and 80 years;\n* No significant comorbidities pain, physical, or mental disorders;\n* No organic, functional changes or systemic diseases that could cause headache;\n* No history of head or neck trauma;\n* No significant abnormalities in blood routine, biochemical tests, coagulation function, or urine routine in the past 12 months prior to enrollment;\n* No alcohol or drug addiction;\n* No pregnancy, breastfeeding, or plans for pregnancy in the next 12 months.\n\nNonrandomized patients with MOH:\n\n●Participants who meet the MOH diagnostic criteria and fulfill the inclusion\u002Fexclusion criteria but decline randomization will be assigned to the non-randomized electroacupuncture group. These participants will receive electroacupuncture treatment directly, with no restrictions on the number of participants per center.",true,{"count":165,"type":21},160,[56],"Acupuncture is commonly used for the prevention of migraine and tension-type headaches, and has been found to be effective in reducing both the frequency and severity of these conditions. However, studies on acupuncture for medication overuse headache (MOH) are limited, and current research has not been able to determine whether its efficacy is due to the actual therapeutic effects of acupuncture or psychological benefits. To address this issue, the investigators have designed a clinical trial to evaluate the efficacy of acupuncture for MOH. In addition, the investigators will explore the regulatory effects of electroacupuncture on central mechanisms in MOH and conduct multi-omics analysis.",[28,169],"Electroacupuncture","2025-07-13",{"date":172,"type":35},"2025-07-16",{"date":174,"type":35},"2025-02-01",{"date":176,"type":21},"2027-06",{"name":178,"class":42},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences"]